Next Article in Journal
Prevalence and Impact of Biofilms on Bloodstream and Urinary Tract Infections: A Systematic Review and Meta-Analysis
Next Article in Special Issue
Anti-Virulence Activity of the Cell-Free Supernatant of the Antarctic Bacterium Psychrobacter sp. TAE2020 against Pseudomonas aeruginosa Clinical Isolates from Cystic Fibrosis Patients
Previous Article in Journal / Special Issue
Polymicrobial Interactions in the Cystic Fibrosis Airway Microbiome Impact the Antimicrobial Susceptibility of Pseudomonas aeruginosa
Article

Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype

1
Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Via Pansini, 5, 80131 Naples, Italy
2
CEINGE–Advanced Biotechnologies, Via G. Salvatore, 486, 80145 Naples, Italy
3
Cystic Fibrosis Regional Reference Center, Department of Pediatric Medicine, Anna Meyer Children’s University, Viale Pieraccini, 24, 50139 Florence, Italy
4
Cystic Fibrosis Center, Hospital San Carlo, Via P. Petrone, 85100 Potenza, Italy
5
Department Reproductive Sciences and Dentistry, University of Naples Federico II of Neuroscience, Via Pansini, 5, 80131 Naples, Italy
*
Author to whom correspondence should be addressed.
Academic Editors: Jose Caparros-Martin and Patricia Agudelo-Romero
Antibiotics 2021, 10(7), 828; https://doi.org/10.3390/antibiotics10070828
Received: 28 May 2021 / Revised: 2 July 2021 / Accepted: 5 July 2021 / Published: 7 July 2021
(This article belongs to the Special Issue The Treatment of Cystic Fibrosis (CF) Disease)
The new CFTR modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the FDA in October 2019 for treatment of Cystic Fibrosis in patients 6 years of age or older who have at least one F508del mutation in one allele and a minimal-function or another F508del mutation in the other allele. However, there is a group of patients, in addition to those with rare mutations, in which despite the presence of a F508del in one allele, it was not possible to identify any mutation in the other allele. To date, these patients are excluded from treatment with Trikafta in Italy, where the CF patients carrying F508del/unknown represent about 1.3% (71 patients) of the overall Italian CF patients. In this paper we show that the Trikafta treatment of nasal epithelial cells, derived from F508del/Unknown patients, results in a significant rescue of CFTR activity. Based on our findings, we think that the F508del/Unknown patients considered in this study could obtain clinical benefits from Trikafta treatment, and we strongly suggest their eligibility for this type of treatment. This study, adding further evidence in the literature, once again confirms the validity of functional studies on nasal cells in the cystic fibrosis theratyping and personalized medicine. View Full-Text
Keywords: theratyping; cystic fibrosis; functional characterization; personalized medicine; CFTR; rare mutation theratyping; cystic fibrosis; functional characterization; personalized medicine; CFTR; rare mutation
Show Figures

Figure 1

MDPI and ACS Style

Comegna, M.; Terlizzi, V.; Salvatore, D.; Colangelo, C.; Di Lullo, A.M.; Zollo, I.; Taccetti, G.; Castaldo, G.; Amato, F. Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype. Antibiotics 2021, 10, 828. https://doi.org/10.3390/antibiotics10070828

AMA Style

Comegna M, Terlizzi V, Salvatore D, Colangelo C, Di Lullo AM, Zollo I, Taccetti G, Castaldo G, Amato F. Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype. Antibiotics. 2021; 10(7):828. https://doi.org/10.3390/antibiotics10070828

Chicago/Turabian Style

Comegna, Marika, Vito Terlizzi, Donatello Salvatore, Carmela Colangelo, Antonella M. Di Lullo, Immacolata Zollo, Giovanni Taccetti, Giuseppe Castaldo, and Felice Amato. 2021. "Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype" Antibiotics 10, no. 7: 828. https://doi.org/10.3390/antibiotics10070828

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop